CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
Welcome to the Lineage Cell Therapeutics Fourth Quarter and Full Year 2022 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the ...
Lineage Cell Therapeutics (NYSE:LCTX) is scheduled to announce Q4 earnings results on Thursday, March 9th, after market close. The consensus EPS Estimate is -$0.04 (vs. -$0.17 last year) and the ...
Lineage Cell Therapeutics, Inc. (AMEX: LCTX) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Welcome to the Lineage Cell Therapeutics Fourth Quarter and Full Year 2022 Conference Call. At ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback